CoChat

Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial

Laffel, Lori M, Danne, Thomas, Klingensmith, Georgeanna J, Tamborlane, William V, Willi, Steven, Zeitler, Philip, Neubacher, Dietmar, Marquard, Jan, Bardymova, Tatiana, Barrientos Perez, Margarita, Bethin, Kathleen, Bjornstad, Petter, Bondar, Irina, Chen, Mimi, Choi, Jin-Ho, Clements, Mark A, Colomar, Javier Ricardo, Daniels, Mark, Deerochanawong, Chaicharn, Desai, Vivek S, Desmangles, Jean-Claude G, Dillon, Robert G, Dixit, Naznin M, Du, Hongwei, Edelen, Rachel, Espinoza Peralta, Diego, Felipe Gacioppo, María Verónica, Ferraz, Tania Maria Bulcão Lousada, Galkina, Galina, Gallagher, Mary Patricia, George, Minu, Gonzalez, Edgar, Gottschalk, Michael Everett, Guido, Giancarlo, Hassan, Amir Ali, Hershkovitz, Eli, Huerta-Saenz, Lina P, Hwang, Jin Soon, Ibarra Gomez, Jaime Orlando, Irizarry Gonzalez, Lydia, Jain, Nina, Jelley, David H, Kim, Ho-Seong, Kovalenko, Tatiana, Laffel, Lori Michelle B, Leichter, Steven B, Liberatore Jr, Raphael Del Roio, Lynch, Jane, Mahmud, Farid Hussain, Malievskiy, Oleg Arturovich, Muir, Andrew, Nelson, Bryce A, Nevarez Ruiz, Luis Alejandro, Olson, Micah L, Pelayo Orozco, Emilia Susana, Peterkova, Valentina, Ramírez Mendoza, Fernando Ramón, Reddy, Konda Mohan, Rodriguez, Henry, Saenz, Javier Andres, Samoilova, Julia, Schwab, Karl-Otfried, Shah, Sejal H, Shehadeh, Naim, Shoemaker, Ashley H, Skorodok, Yulia, Sobolev, Aleksandr, Solís, Silvana Ernestina, Srinivasan, Shylaja, Tamborlane, William V, Tsalikian, Eva, Valeeva, Farida, Vance, Carl D, Velasquez-Mieyer, Pedro A, Violante Ortiz, Rafael Margarito, Votyakova, Olga, Wei, Haiyan, Weinstock, Ruth S, Wheeler, Mark D, Wicklow, Brandy Alexandra, Willi, Steven M, Wintergerst, Kupper A, Wolf, Risa M, Wood, Jamie Ruth, Yaliwal, Chandan, Yupanqui Lozno, Hernán · 2023 · The Lancet Diabetes & Endocrinology
Cited by 106

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(22)00387-4

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Research works printed but not linked: 22

  1. Darnton-Hill, 2004, A life course approach to diet, nutrition and the prevention of chronic diseases, Public Health Nutr, 7, 101, 10.1079/PHN2003584 · DOI · Paper page
  2. Al-Saeed, 2016, An inverse relationship between age of type 2 diabetes onset and complication risk and mortality: the impact of youth-onset type 2 diabetes, Diabetes Care, 39, 823, 10.2337/dc15-0991 · DOI · Paper page
  3. Lawrence, 2021, Trends in prevalence of type 1 and type 2 diabetes in children and adolescents in the US, 2001–2017, JAMA, 326, 717, 10.1001/jama.2021.11165 · DOI · Paper page
  4. 2013, Rapid rise in hypertension and nephropathy in youth with type 2 diabetes: the TODAY clinical trial, Diabetes Care, 36, 1735, 10.2337/dc12-2420 · DOI · Paper page
  5. Dabelea, 2017, Association of type 1 diabetes vs type 2 diabetes diagnosed during childhood and adolescence with complications during teenage years and young adulthood, JAMA, 317, 825, 10.1001/jama.2017.0686 · DOI · Paper page
  6. Shah, 2022, ISPAD clinical practice consensus guidelines 2022: type 2 diabetes in children and adolescents, Pediatr Diabetes, 23, 872, 10.1111/pedi.13409 · DOI · Paper page
  7. Arslanian, 2022, Once-weekly dulaglutide for the treatment of youths with type 2 diabetes, N Engl J Med, 387, 433, 10.1056/NEJMoa2204601 · DOI · Paper page
  8. Tamborlane, 2019, Liraglutide in children and adolescents with type 2 diabetes, N Engl J Med, 381, 637, 10.1056/NEJMoa1903822 · DOI · Paper page
  9. Tamborlane, 2022, Once-weekly exenatide in youth with type 2 diabetes, Diabetes Care, 45, 1833, 10.2337/dc21-2275 · DOI · Paper page
  10. Shankar, 2022, A randomized clinical trial of the efficacy and safety of sitagliptin as initial oral therapy in youth with type 2 diabetes, Pediatr Diabetes, 23, 173, 10.1111/pedi.13279 · DOI · Paper page
  11. Tamborlane, 2022, Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study, Lancet Diabetes Endocrinol, 10, 341, 10.1016/S2213-8587(22)00052-3 · DOI
  12. Laffel, 2018, Pharmacokinetic and pharmacodynamic profile of the sodium-glucose co-transporter-2 inhibitor empagliflozin in young people with Type 2 diabetes: a randomized trial, Diabet Med, 35, 1096, 10.1111/dme.13629 · DOI
  13. Tamborlane, 2018, Randomized, double-blind, placebo-controlled dose-finding study of the dipeptidyl peptidase-4 inhibitor linagliptin in pediatric patients with type 2 diabetes, Pediatr Diabetes, 19, 640, 10.1111/pedi.12616 · DOI
  14. Karres, 2014, Joining forces: a call for greater collaboration to study new medicines in children and adolescents with type 2 diabetes, Diabetes Care, 37, 2665, 10.2337/dc14-0494 · DOI
  15. Mangione, 2022, Screening for prediabetes and type 2 diabetes in children and adolescents: US Preventive Services Task Force recommendation statement, JAMA, 328, 963, 10.1001/jama.2022.14543 · DOI · Paper page
  16. Isganaitis, 2022, Recommendations for screening children and adolescents for prediabetes and type 2 diabetes, JAMA, 328, 933, 10.1001/jama.2022.13759 · DOI
  17. Jonas, 2022, Screening for prediabetes and type 2 diabetes in children and adolescents: evidence report and systematic review for the US Preventive Services Task Force, JAMA, 328, 968, 10.1001/jama.2022.7957 · DOI
  18. Tamborlane, 2018, Eligibility for clinical trials is limited for youth with type 2 diabetes: insights from the pediatric diabetes consortium T2D clinic registry, Pediatr Diabetes, 19, 1379, 10.1111/pedi.12763 · DOI
  19. Mansournia, 2016, Inverse probability weighting, BMJ, 352, i189, 10.1136/bmj.i189 · DOI · Paper page
  20. Zeitler, 2012, A clinical trial to maintain glycemic control in youth with type 2 diabetes, N Engl J Med, 366, 2247, 10.1056/NEJMoa1109333 · DOI · Paper page
  21. Bacha, 2018, Initial presentation of type 2 diabetes in adolescents predicts durability of successful treatment with metformin monotherapy: insights from the pediatric diabetes consortium T2D registry, Horm Res Paediatr, 89, 47, 10.1159/000481687 · DOI
  22. Malik, 2022, Trends in glycemic control among youth and young adults with diabetes: the SEARCH for diabetes in youth study, Diabetes Care, 45, 285, 10.2337/dc21-0507 · DOI · Paper page

Cited by

See all 106

Metadata

Authors
Laffel, L. M., Danne, T., Klingensmith, G. J., Tamborlane, W. V., Willi, S., Zeitler, P., Neubacher, D., Marquard, J., Bardymova, T., Barrientos Perez, M., Bethin, K., Bjornstad, P., Bondar, I., Chen, M., Choi, J.-H., Clements, M. A., Colomar, J. R., Daniels, M., Deerochanawong, C., Desai, V. S., Desmangles, J.-C. G., Dillon, R. G., Dixit, N. M., Du, H., Edelen, R., Espinoza Peralta, D., Felipe Gacioppo, M. V., Ferraz, T. M. B. L., Galkina, G., Gallagher, M. P., George, M., Gonzalez, E., Gottschalk, M. E., Guido, G., Hassan, A. A., Hershkovitz, E., Huerta-Saenz, L. P., Hwang, J. S., Ibarra Gomez, J. O., Irizarry Gonzalez, L., Jain, N., Jelley, D. H., Kim, H.-S., Kovalenko, T., Laffel, L. M. B., Leichter, S. B., Liberatore Jr, R. D. R., Lynch, J., Mahmud, F. H., Malievskiy, O. A., Muir, A., Nelson, B. A., Nevarez Ruiz, L. A., Olson, M. L., Pelayo Orozco, E. S., Peterkova, V., Ramírez Mendoza, F. R., Reddy, K. M., Rodriguez, H., Saenz, J. A., Samoilova, J., Schwab, K.-O., Shah, S. H., Shehadeh, N., Shoemaker, A. H., Skorodok, Y., Sobolev, A., Solís, S. E., Srinivasan, S., Tamborlane, W. V., Tsalikian, E., Valeeva, F., Vance, C. D., Velasquez-Mieyer, P. A., Violante Ortiz, R. M., Votyakova, O., Wei, H., Weinstock, R. S., Wheeler, M. D., Wicklow, B. A., Willi, S. M., Wintergerst, K. A., Wolf, R. M., Wood, J. R., Yaliwal, C., & Yupanqui Lozno, H.
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2023-03
Volume
11
Issue
3
Pages
169-181
ISSN
2213-8587
Cited by
106
References
14
Language
en
Funders
  • Boehringer Ingelheim
  • Boehringer Ingelheim International GmbH

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial. https://app.cochat.ai/papers/10.1016/s2213-8587(22)00387-4
The paper
Laffel, L. M., Danne, T., Klingensmith, G. J., Tamborlane, W. V., Willi, S., Zeitler, P., Neubacher, D., Marquard, J., Bardymova, T., Barrientos Perez, M., Bethin, K., Bjornstad, P., Bondar, I., Chen, M., Choi, J.-H., Clements, M. A., Colomar, J. R., Daniels, M., Deerochanawong, C., . . . Yupanqui Lozno, H. (2023). Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(22)00387-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.